# (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

### (19) World Intellectual Property Organization

International Bureau

(43) International Publication Date 23 December 2004 (23.12.2004)



## NET I GOVERNO DE REVINO COMO CENTO ELLOS ELLOS DE ROY COMO DERRO COMO CINCO ENCOCENTRA RELEGIA FILIDA CONTRA C

**PCT** 

(10) International Publication Number WO 2004/110452 A1

- (51) International Patent Classification?: A61K 31/505. C07D 239/42, 401/04, 401/14, 403/04, 417/04, A61K 31/506, A61P 35/00
- (21) International Application Number:

PCT/EP2004/006317

- (22) International Filing Date: 11 June 2004 (11.06.2004)
- (25) Filing Language:

English

(26) Publication Language:

**English** 


(30) Priority Data: 60/478,709

13 June 2003 (13.06.2003)

- (74) Agent: GRUBB, Philip; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FL GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

with international search report

For two-letter codes and other abbrevlations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



(57) Abstract: This application discloses compounds that inhibit Raf kinase having the formula (I), wherein  $R_1$  is a phenyl radical or a heteroaryl radical; and  $R_2$  is a phenyl radical; or an N-oxide or a pharmaceutically acceptable salt thereof. The compounds are useful for the treatment of proliferative diseases, such as cancer.